Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295178 · ClinicalTrials.gov registry record · Phase 4
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
A Phase 4 study of Cellulitis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00295178: Completed Phase 4 study of Cellulitis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00295178 is a Phase 4 study of Cellulitis that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 80 participants, below the 563-participant average among 11 other Cellulitis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295178, a Phase 4 study of Cellulitis, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: * Time to erythema margin cessation to progress * Time to defervescence * Time to hospital discharge following relief of the presenting cellulitis or erysipelas * Degree of improvement of the following signs and symptom of cellulitis or erysipelas including * Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Daptomycin
Study Locations (1)
Georgia
- Joseph Still Research Foundation - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-02-20 |
| Est. Completion | 2006-08-09 |
| Phase | Phase 4 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
What the finished NCT00295178 record still lists
NCT00295178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 563-participant average among 11 other Cellulitis trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Cellulitis appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT00295178 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00295178 about?
NCT00295178 is a clinical study titled "Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas". This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: * Time to erythema margin cessation to progress * Time to defervescence * Time...
What is the current status of trial NCT00295178?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2006-02-20. Estimated completion is 2006-08-09.
What conditions does trial NCT00295178 study?
This clinical trial studies the following conditions: Cellulitis.
What interventions are being tested in trial NCT00295178?
The interventions under investigation include: Vancomycin (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT00295178?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00295178 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00295178's enrollment target sits among peer trials
80 11th of 11 higher than 1 of 11 other Cellulitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cellulitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
COMPLETED · Phase 4
-
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
ACTIVE NOT RECRUITING · NA
-
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
COMPLETED · Phase 2
-
Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department
COMPLETED
-
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
COMPLETED · NA
-
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI